Q&A: Timothy Mayleben, CEO of Aastrom Biosciences Print E-mail
By Staff and Wire Reports   
Monday, 09 April 2012 08:50

Last month, Aastrom Biosciences, announced that it had completed an impressive, $40 million private placement financing. The development was noted as a particularly bullish sign for emerging biotechs everywhere.

In an exclusive interview, Timothy M. Mayleben, who has served as Aastrom's President and CEO since late 2009, explains how the financing came together and why investors sought out his firm to place the big bet on their future.

Mayleben, who previously served as an advisor to life science and healthcare companies through his advisory and investment firm, ElMa Advisors, was also formerly the COO of Esperion Therapeutics which later became a division of Pfizer Global Research & Development. He holds an MBA, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University and a BBA from the University of Michigan Ross School of Business.

His firm, Aastrom Biosciences, is one of the most exciting regenerative medicine companies in the healthcare sector. They are engaged in the development of autologous cell products for treatment of severe, chronic cardiovascular diseases. Their proprietary cell-processing technology enables the manufacture of ixmyelocel-T, a patient-specific multicellular therapy expanded from a patient's own bone marrow and delivered directly to damaged tissues. The cellular therapy resulting from this process contains expanded populations of mixed stem and progenitor cells to support the regeneration of cardiovascular tissue. The company's cell manufacturing process works exclusively with adult stem cells derived from and administered to the same patient. This approach reduces the risk of rejection and increases the likelihood of integration with the surrounding tissues, eliminating the need for immunosuppressive drugs.

His exclusive interview with BioMedReports appears below:




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter